Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TMB

Bristol Myers Squibb logo

FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC

A verdict is expected to be delivered by 15 May

Bristol Myers Squibb logo

BMS expands collaboration with Nektar, sending shares soaring

Adds research programmes in an additional two cancer types

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combination fails to shine in melanoma

Combo therapy did not show significant benefit in key patient population

Bristol Myers Squibb logo

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

Possible new treatment for difficult to treat cancer type

Bristol Myers Squibb logo

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

Group sales rose 6% to $6bn in the third quarter

- PMLiVE

AZ’s Imfinzi combo scores in front-line lung cancer

Attempts to catch up to BMS and Merck in non-small cell lung cancer

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combo scores in front-line lung cancer

Makes case for duo therapy in NSCLC patients

- PMLiVE

BMS plugs on with Opdivo plus Yervoy in first-line NSCLC

Could be an alternative treatment option to chemotherapy

- PMLiVE

Breath test could predict response to immunotherapy

Study found device accurately predicted responses in lung cancer

- PMLiVE

Third strike for BMS’ Opdivo in brain cancer

Despite failing first endpoint, trial is set to continue

- PMLiVE

MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups

- PMLiVE

Amgen snaps up Celgene’s Otezla for $13.4bn

Higher-than-expected price helps BMS sweeten merger deal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links